bims-glucam Biomed News
on Glutamine cancer metabolism
Issue of 2026–10–18
twenty-two papers selected by
Sreeparna Banerjee, Middle East Technical University



  1. Rev Cardiovasc Med. 2026 Sep;27(9): 51889
      Cardiac hypertrophy represents a crucial adaptive response of the heart to various physiological and pathological stimuli, with metabolic reprogramming serving as the core mechanism driving this process. In recent years, the role of glutamine metabolism in cardiac hypertrophy has garnered increasing attention. This review systematically elucidates the similarities and differences in glutamine metabolism between physiological and pathological cardiac hypertrophy, with a focus on the dual role of glutamine metabolism in regulating cardiomyocyte hypertrophy: it has a protective effect by maintaining energy metabolism and reducing oxidative stress, while simultaneously contributing to the hypertrophic process by promoting anabolic metabolism and exacerbating metabolic remodeling. The subsequent analysis delved into the specific mechanisms by which glutamine metabolism regulates cardiomyocyte hypertrophy, focusing on the functions of key metabolic enzymes and transporters that collectively govern glutamine flux and its downstream signaling pathways. Furthermore, we explore the intricate interplay between glutamine metabolism and lipid metabolism, which plays a pivotal role in cardiac energy homeostasis and hypertrophic development. Finally, we discuss the potential of targeting glutamine metabolism as a therapeutic strategy, highlighting the novel therapeutic prospects of glutamine supplementation in cardiac diseases. In summary, as a key component of metabolic reprogramming in cardiomyocyte hypertrophy, glutamine metabolism offers deeper insights into the pathophysiological mechanisms of cardiac hypertrophy. Future interventions targeting the glutamine metabolic pathway could prevent and treat pathological cardiac hypertrophy.
    Keywords:  cardiac hypertrophy; glutamine metabolism; metabolic enzyme; metabolic reprogramming; transporter
    DOI:  https://doi.org/10.31083/RCM51889
  2. Elife. 2026 Oct 12. pii: RP108336. [Epub ahead of print]14
      To maintain metabolic homeostasis, enzymes must adapt to fluctuating nutrient levels through mechanisms beyond gene expression. Here, we demonstrate that human glutamine synthetase (GS) can reversibly polymerize into filaments aided by a composite binding site formed at the filament interface by the product, glutamine. Time-resolved cryo-electron microscopy (cryo-EM) confirms that glutamine binding stabilizes these filaments, which in turn exhibit reduced catalytic specificity for ammonia at physiological concentrations. This inhibition appears induced by a conformational change that remodulates the active site loop ensemble gating substrate entry. Metadynamics ensemble refinement revealed >10 Å conformational range for the active site loop and that the loop is stabilized by transient contacts. This disorder is significant, as we show that the transient contacts which stabilize this loop in a closed conformation are essential for catalysis both in vitro and in cells. We propose that GS filament formation constitutes a negative-feedback mechanism, directly linking product concentration to the structural and functional remodeling of the enzyme.
    Keywords:  E. coli; biochemistry; chemical biology; cryo-EM; ensembles; filaments; glutamine synthetase; human; metabolism; molecular biophysics; structural biology
    DOI:  https://doi.org/10.7554/eLife.108336
  3. Pharmacol Rep. 2026 Oct 14.
       BACKGROUND: Glioblastoma (GBM) exhibits extensive metabolic reprogramming, including glucose and glutamine (Gln) addiction, with Gln being converted into glutamate by glutaminase, encoded by the GLS and GLS2 genes. GLS2 acts as a context-dependent tumor suppressor, although the underlying mechanisms remain poorly understood. GLS2 is silenced in GBM, and we previously showed that its re-expression modulates pyruvate dehydrogenase (PDH) activity and tricarboxylic acid cycle (TCAC) metabolism, suggesting a distinct metabolic rewiring associated with its tumor-suppressive function.
    METHODS: LN229 and T98G GBM cell lines were used as experimental models. Metabolomic profiling by liquid chromatography-mass spectrometry was performed to compare changes in central metabolic pathways following GLS2 or GLS overexpression. Glutaminase and PDH enzymatic activities were measured, and Western blotting was performed to assess GLS, GLS2, and PDHA1 protein levels and PDHA1 phosphorylation. A Seahorse analyzer was employed to quantify real-time ATP production derived from glycolysis and oxidative phosphorylation.
    RESULTS: Overexpression of GLS2, but not GLS, in LN229 cells caused the accumulation of TCAC-related metabolites, except for citrate, whose depletion is attributed to GLS2's effect on PDH phosphorylation, causing reduced PDH activity. This was accompanied by decreased levels of several acyl-carnitines. Furthermore, GLS2 induced the accumulation of glucose/fructose, while reducing levels of glucose-6-phosphate and pentose-phosphates, consistent with altered glycolysis. GLS2 also diminished the ATP/AMP ratio, confirmed by a reduced ATP synthesis rate, particularly glycolytic ATP, whereas mitochondrial ATP production remained unaltered.
    CONCLUSIONS: GLS2 exerts an isoenzyme-specific effect on Gln and glucose metabolism in GBM, likely modulating the glycolysis/pentose-phosphate pathway (PPP)-TCAC-axis.
    Keywords:  Cancer metabolism; GLS2; Glioblastoma; Glutaminase; Glutamine; Pyruvate dehydrogenase
    DOI:  https://doi.org/10.1007/s43440-026-00908-9
  4. Metab Eng. 2026 Oct 15. pii: S1096-7176(26)00162-X. [Epub ahead of print] 102567
      Extracellular vesicles (EVs) are mediators of intercellular communication, yet their impact on Chinese Hamster Ovary (CHO) cell physiology and bioprocess performance remains poorly understood. Here, we investigated whether small EVs (sEVs) and large EVs (LgEVs) that accumulate during fed-batch and perfusion cultures modulate CHO cell growth, metabolism, apoptosis, and monoclonal antibody (mAb) production. EVs isolated from early- and late-stage cultures were added to fresh CHO cultures grown with or without glutamine supplementation. Only LgEVs had a significant impact. Late-stage LgEVs markedly altered CHO-cell behavior, reducing cell proliferation, increasing apoptosis under glutamine-limited conditions, and substantially enhancing mAb productivity in a dose-dependent manner. Glutamine supplementation largely alleviated the growth-inhibitory and pro-apoptotic effects of LgEVs while preserving their positive impact on productivity, suggesting that glutamine mitigated the EV-mediated stress without affecting the productivity enhancement. Metabolic analyses revealed increased glucose consumption, a glutamine-dependent shift between glycine and alanine overflow metabolism, and remodeling of amino-acid utilization. Metabolic flux analysis further demonstrated enhanced glycolytic overflow and increased reliance on amino acid-supported anaplerosis. Conversely, selective removal of LgEVs from perfusion medium significantly improved cell expansion without reducing antibody production, supporting an inhibitory role for late-stage LgEVs. These LgEVs were enriched in let-7 family miRNAs and miR-21, consistent with RNAseq analyses demonstrating stress-associated enrichment of these miRNAs in CHO EVs and with functional studies showing that let-7a and miR-21reduce CHO-cell growth. Together, these observations suggest that selective miRNA loading contributes to the growth, metabolic, and productivity phenotypes elicited by late-stage LgEVs. Our findings identify LgEVs in CHO-K1 can act as endogenous regulators of CHO-cell physiology thus deserving attention for optimizing high-density fed-batch and perfusion biomanufacturing processes.
    Keywords:  Chinese Hamster Ovary (CHO) cells; Extracellular vesicles (EVs); Glutamine metabolism; Large extracellular vesicles (LgEVs); Metabolic flux analysis (MFA); Overflow metabolism; Perfusion biomanufacturing
    DOI:  https://doi.org/10.1016/j.ymben.2026.102567
  5. Biochim Biophys Acta Rev Cancer. 2026 Oct 15. pii: S0304-419X(26)00210-6. [Epub ahead of print] 189738
      Cancer stem cells (CSCs) play a pivotal role in therapeutic resistance, metastasis, and tumour recurrence. During treatment, these cells undergo dynamic changes that enable survival and metabolic adaptation, leading to poor clinical outcomes. CSCs are capable of developing resistance to drugs by alterations in the metabolic and signalling pathways. They exhibit metabolic adaptations that enable therapy resistance, tumour recurrence, and metastasis. These adaptations involve shifts in glycolysis, oxidative phosphorylation (OXPHOS), lipid and amino acid metabolism, mitochondrial dynamics, and interactions with the tumour microenvironment to support energy production. Depending on the biological contexts and the energy needs, CSCs can switch to different metabolic phenotypes. CSCs drive energy production and biogenesis via glycolysis in hypoxic conditions. OXPHOS is essential for sustaining cell dormancy, survival and carcinogenesis. In addition to glycolysis and OXPHOS, CSCs employ lipid metabolism for energy production via fatty acid oxidation and amino acids metabolism via glutamine metabolism promoting redox balancing and epigenetic modifications. Taken together, this metabolic plasticity facilitates CSC survival and treatment resistance. Besides, CSCs are capable of metabolically rewiring their niche to evade apoptosis, enhance DNA repair, and promote immune evasion, which are considered hallmarks of drug resistance and cancer relapse. An in-depth understanding of the metabolic network and signalling pathways of CSCs may help in developing combination or targeted therapies against them, thereby increasing the potential to formulate effective treatment approaches for the complete eradication of cancer/CSCs. This review addresses dynamic changes in the CSCs' metabolism and signalling leading to the development of drug-resistance phenotype, causing survival and relapse in the tumours. Therapeutic strategies targeting CSC metabolism and signalling via metabolic modulators and stemness inhibitor were discussed. Overall, CSC metabolic adaptation promotes drug resistance and tumour proliferation. Hence targeting these metabolic adaptations offers new perspective for the elimination of CSCs and enhanced therapy.
    Keywords:  Apoptosis; Metabolism; Resistance; Signalling; Stemness; cancer
    DOI:  https://doi.org/10.1016/j.bbcan.2026.189738
  6. Acute Crit Care. 2026 Oct 15.
       Background: Studies evaluating intravenous (IV) glutamine supplementation in critically ill patients have shown inconsistent results. This study aimed to evaluate the effects of IV glutamine on mortality, infectious complications, length of stay, and duration of mechanical ventilation.
    Methods: A systematic search of Ovid Medline, Embase, the Cochrane Central Register of Controlled Trials, and KoreaMed was conducted from inception through October 2023 and updated in April 2025. Randomized controlled trials comparing IV glutamine supplementation with standard care in critically ill adults were included. Pooled estimates were calculated using random-effects models.
    Results: A total of 10 randomized trials involving 1,593 critically ill patients were included in the analysis. IV glutamine supplementation was not associated with reduced overall mortality (risk ratio [RR], 0.93; 95% CI, 0.77-1.13) or overall infection rates (RR, 0.86; 95% CI, 0.63-1.18). No mortality benefit was observed in either non-surgical or surgical/trauma subgroups. Glutamine supplementation was associated with reduced pneumonia incidence (RR, 0.65; 95% CI, 0.49-0.87) and shorter mechanical ventilation duration (mean difference, -0.97 days; 95% CI, -1.62 to -0.32); however, these findings were based on a limited number of small studies. Intensive care unit and hospital length of stay were longer in the glutamine group.
    Conclusions: IV glutamine supplementation was not associated with improved survival or overall infection rates in critically ill adults. Current evidence does not support routine IV glutamine supplementation in unselected critically ill patients.
    Keywords:  critical care; critical illness; glutamine; meta-analysis; parenteral nutrition; systematic review
    DOI:  https://doi.org/10.4266/acc.002132
  7. Nat Prod Res. 2026 Oct 15. 1-5
      Triptolide exhibits significant toxicity. This study aims to investigate its toxicological biomarkers and metabolic pathways using a metabolomics approach in a zebrafish model. This study investigated toxicological biomarkers and metabolic pathways of triptolide in zebrafish exposed to 20, 180, or 360 ng/mL for 96 h. Untargeted UPLC-MS metabolomics revealed 3, 4, and 26 significantly altered metabolites in low‑, medium‑, and high‑dose groups, respectively. In the high‑dose group, acylcarnitines, glutamine, glutathione, inosine‑5'‑monophosphate (IMP), betaine, taurine, creatine, and hypoxanthine decreased, while glycerophosphocholine, deoxyguanosine, and 12‑hydroxyoctadecanoic acid increased. Pearson correlation identified guanine, deoxyguanosine, IMP, glycerophosphocholine, taurine, and oleoyl‑L‑carnitine as mortality‑correlated biomarkers. Pathway enrichment pointed to purine and amino acid metabolism. These findings provide a foundation for understanding triptolide's toxicological mechanisms.
    Keywords:  Metabolomics; amino acid metabolism; purine metabolism; toxicity; zebrafish
    DOI:  https://doi.org/10.1080/14786419.2026.2748466
  8. Ann Biomed Eng. 2026 Oct 11.
      Glucose and oxygen availability are fundamental drivers of tumor progression, deeply influencing cancer cell proliferation, metabolism, and spatial organization. In this study, we present a simplified microfluidic-based 3D model of tumorigenesis that allows for controlled and dynamic analysis of key tumor parameters under metabolic stress. Using this platform, lung adenocarcinoma (A549) spheroids embedded in a collagen-based extracellular matrix were monitored over time to assess growth kinetics, hypoxic response via HIF-1α expression, and structural organization. A multifactorial experimental design combining variations in glucose, glutamine, and oxygen availability revealed distinct and specific effects of each nutrient. Glutamine deprivation led to widespread cell death, while glucose limitation strongly arrests cell proliferation. Finally, oxygen restriction disrupted spheroid architecture, resulting in loss of the proliferative outer capsule and the formation of internal cavities. Our approach provides a flexible system to study how microenvironmental cues shape tumor behavior, offering insights into metabolic vulnerabilities and the morphofunctional consequences of nutrient stress in cancer.
    Keywords:  3D cell culture; Cancer spheroids; Glucose depletion; HIF-1α; Hypoxia
    DOI:  https://doi.org/10.1007/s10439-026-04377-2
  9. Bioprocess Biosyst Eng. 2026 Oct 16.
      Chinese hamster ovary (CHO) cells are the workhorse of biopharmaceutical manufacturing, yet lactate and ammonia accumulation remain persistent bottlenecks that compromise cell viability, productivity, and product quality. To address this, we present an integrated feeding strategy systematically combining Ala-Gln, TCA intermediates, and glucose-galactose dual carbon feed evaluated head-to-head across four defined fed-batch conditions for CHO cultures producing an IgG1 monoclonal antibody (mAb). Conventional L-glutamine was replaced with L-alanyl-glutamine (Ala-Gln) to curb spontaneous ammonia release, while a customized "efficient feed mix" enriched with 2× TCA cycle intermediates and branched-chain amino acids combined with a glucose-galactose co-feed (2 mM glucose + 30 mM galactose) was introduced upon glucose depletion. Four fed-batch conditions were evaluated: a glutamine control (FB-01), Ala-Gln alone (FB-02), Ala-Gln with TCA intermediates (FB-03), and the complete integrated strategy (FB-04). FB-04 delivered an > 83% reduction in peak lactate (4.0 mM) and 80% reduction in ammonia (< 2.0 mM), sustained cell viability above 85% through day 11, and achieved a 93% higher mAb titre (1.72 g/L) with peak Viable count density (VCD) of 39 × 10⁶ cells/mL. Glycosylation profiles (19.0% galactosylation) remained aligned with innovator benchmarks. This study presents the first direct head-to-head benchmarking of Ala-Gln substitution, TCA intermediate supplementation, and galactose co-feeding in a single CHO fed-batch platform, demonstrating their combined metabolic and glycosylation benefits against a glutamine control.
    Keywords:  Ala-Gln; Ammonia reduction; Chinese hamster ovary cells; Fed-batch fermentation; Lactate mitigation; Metabolic optimization; Monoclonal antibody; TCA cycle intermediates
    DOI:  https://doi.org/10.1007/s00449-026-03444-1
  10. Drug Chem Toxicol. 2026 Oct 11. 1-11
      Bisphenol A (BPA) is a widely utilized endocrine-disrupting chemical that has been associated with metabolic dysregulation in various tissues. Nevertheless, its impact on ocular metabolism remains insufficiently understood. This study aims to investigate the metabolic effects of BPA exposure in ARPE-19 retinal pigment epithelial cells using untargeted metabolomics. ARPE-19 cells were exposed to 100 µM BPA for 24 hours, and cytotoxicity, intracellular reactive oxygen species (ROS) levels and glutathione metabolism parameters were identified. Metabolic alterations were analyzed utilizing liquid chromatography-quadrupole time-of-flight mass spectrometry (Q-TOF LC/MS). Principal component analysis (PCA), volcano plots, heatmaps, and pathway enrichment analysis were conducted to identify significantly altered metabolites and pathways. BPA exposure led to notable metabolic changes, including alterations in the tricarboxylic acid (TCA) cycle, β-oxidation, nucleoside metabolism, and amino acid metabolism. Key metabolite changes included increased levels of glutamine, pyroglutamic acid, anserine, and adenosine 2',3'-cyclic phosphate, suggesting oxidative stress and metabolic adjustment. Pathway analysis identified significant changes in arachidonic acid metabolism and pyrimidine metabolism, indicating oxidative stress and metabolic compensation due to BPA exposure. The findings underscore the metabolic risks of BPA exposure to retinal health and necessitate further validation through targeted metabolomics and in vivo studies.
    Keywords:  Bisphenol A (BPA); energy metabolism; metabolomics; oxidative stress; retinal pigment epithelium (RPE)
    DOI:  https://doi.org/10.1080/01480545.2026.2697203
  11. Cancers (Basel). 2026 Oct 03. pii: 3202. [Epub ahead of print]18(19):
      Metabolic reprogramming is increasingly recognised as a central determinant of bladder cancer heterogeneity, immune regulation and treatment response. This review integrates genetic, epigenetic, microenvironmental and therapeutic evidence to explain how bladder cancer redistributes carbon and nitrogen across glycolysis, lipid synthesis and oxidation, amino-acid metabolism and mitochondrial respiration. Alterations in FGFR3, PIK3CA, MYC, TP53/RB1 and KDM6A establish distinct, context-dependent metabolic dependencies, while hypoxia, extracellular-matrix mechanics and treatment selection reinforce metabolic plasticity. These programmes influence not only energy production and biosynthesis but also ferroptosis, genome stability and chromatin or RNA regulation. Lactate, adenosine, kynurenine and asparagine further connect tumour metabolism to regulatory T cells, myeloid cells, innate immune sensing and CD8-positive T cell function, thereby shaping resistance to chemotherapy and immune-checkpoint blockade. Therapeutic opportunities include targeting glycolysis, fatty-acid and cholesterol metabolism, glutamine and proline metabolism, arginine auxotrophy and metabolite-mediated immune suppression. However, pathway redundancy, cellular heterogeneity and shared metabolic requirements between tumour and immune cells constrain unselected treatment. Urine, tissue, blood and imaging metabolomics offer complementary routes to diagnosis, prognostication and real-time response monitoring, but require harmonised sampling, functional flux measurements and prospective validation. A clinically useful strategy will therefore depend on defining metabolic vulnerabilities by genotype, cell type, spatial context and treatment stage, and on pairing pharmacodynamic biomarkers with rational combinations and local delivery where appropriate.
    Keywords:  biomarker; bladder cancer; chemotherapy; immunotherapy; metabolic reprogramming; pathogenesis
    DOI:  https://doi.org/10.3390/cancers18193202
  12. Clin Sci (Lond). 2026 Nov 11. 140(11): 2363-2385
      Immune cell function is tightly coupled to cellular metabolism, with glycolysis, oxidative phosphorylation, and amino acid and lipid metabolism governing activation, differentiation, survival, and effector responses. In rheumatoid arthritis (RA), an autoimmune disease characterized by destructive joint inflammation, metabolic checkpoints have emerged as critical regulators of immune-cell behavior and drivers of tissue pathology. RA CD4+ T cells undergo profound metabolic reprogramming: glycolysis is suppressed, and glucose is redirected into the pentose phosphate pathway, resulting in NADPH accumulation, reduced ROS levels, and a highly reductive intracellular environment. Concurrent defects in mitochondrial DNA repair and electron transport chain function compromise mitochondrial fitness, leading to NAD+ depletion, altered tricarboxylic acid cycle activity, and metabolic exhaustion. The resulting accumulation of citrate and acetyl-CoA promotes lipogenesis and protein acetylation, driving membrane remodeling, tissue invasiveness, and proinflammatory effector functions. Depletion of oxaloacetate and aspartate limits NAD+ regeneration, inducing endoplasmic reticulum expansion and enhanced tumor necrosis factor production. Defective lysosomal coordination of AMPK and mTORC1 signaling uncouples energy sensing from anabolic programs, enabling cellular activation and proliferation despite metabolic insufficiency. Macrophage fate and function are similarly shaped by metabolic state. In synovial macrophages, GLUD1-dependent glutamine oxidation sustains mitochondrial respiration and ATP production, enabling survival under nutrient-deprived conditions while promoting antigen presentation. Conversely, metabolic stress in MerTK+ macrophages activates the NAD+ hydrolase SARM1, triggering NAD+ depletion, mitochondrial collapse, and PANoptotic cell death. Together, these findings identify NAD+ availability, mitochondrial fitness, and organelle-based signaling as central metabolic gatekeepers linking bioenergetic stress to immune-cell dysfunction and chronic inflammation in RA.
    Keywords:  T-cells; glycolysis; lysosomes; mitochondria; oxidative phosphorylation; rheumatoid arthritis
    DOI:  https://doi.org/10.1042/CS20250834
  13. Cell Rep. 2026 Oct 15. pii: S2211-1247(26)01131-9. [Epub ahead of print]45(10): 118053
      Ataxin-2 (ATXN2) is a genetic modifier of TDP-43 toxicity and a promising therapeutic target in amyotrophic lateral sclerosis (ALS). However, the mechanisms underlying its neuroprotective effects remain poorly understood. Using global proteomic profiling in yeast and mouse TDP-43 models, we establish that pbp1/ataxin-2 (pbp1 is the yeast ataxin-2 ortholog) reduction confers neuroprotection by activating orthogonal stress-adaptive pathways in neurons and glia, rather than simply reversing TDP-43-induced damage. In neurons, ataxin-2 downregulation activates glycolysis and reductive glutamine carboxylation driven by IDH1, restoring ATP production independently of impaired mitochondria. In astrocytes, it upregulates cholesterol biosynthesis via HMGCS1, enhancing trophic support to neurons. Full neuroprotection requires both mechanisms: neuronal survival is only completely rescued when ataxin-2 is reduced in neuron-astrocyte co-cultures. Importantly, ataxin-2 downregulation protects against both TDP-43 gain- and loss-of-function toxicity, broadening its therapeutic relevance. Collectively, these findings establish ataxin-2 as a regulator of stress-adaptive metabolic resilience.
    Keywords:  ALS; ALS therapy; CP: metabolism; CP: neuroscience; TDP-43; ataxin-2; cholesterol; glutamine reductive carboxylation; glycolysis; mechanisms of neuroprotection; neurodegeneration; neuronal metabolism; neuroprotection
    DOI:  https://doi.org/10.1016/j.celrep.2026.118053
  14. Arch Med Sci. 2026 ;22(4): 2231-2249
      Ferroptosis is a programmed cell death characterized by excessive, iron-dependent accumulation of membrane lipid peroxides due to insufficient glutathione-dependent antioxidant defense. It is influenced by the metabolism of amino acids, lipids, and iron, and occurs in conditions of decreased glutathione peroxidase 4 (GPX4) activity. The increased polyunsaturated fatty acid (PUFA) content in membrane phospholipids is associated with cellular hypersusceptibility to ferroptosis. In contrast, incorporation of monounsaturated fatty acids may protect cells against ferroptotic cell death. Cellular sensitivity to ferroptosis is additionally influenced by glutamine catabolism and the xc-system-mediated import of cystine, which modulate glutathione production, and by elevated iron levels, which lead to the buildup of reactive oxygen species (ROS) that attack membrane-localized PUFAs. This review focuses on recent findings of perturbed metabolic processes in cancer that create a high iron demand and an altered lipid composition, thereby predisposing cells to ferroptosis. We analyze the therapeutic potential of pharmacological agents that can selectively trigger ferroptosis in tumor cells.
    Keywords:  GPX4; cancer therapeutics; ferroptosis; glutathione metabolism; iron metabolism; lipid metabolism; redox homeostasis
    DOI:  https://doi.org/10.5114/aoms/225096
  15. Expert Opin Pharmacother. 2026 Oct 16.
       INTRODUCTION: Repurposing inexpensive oral compounds targeting metabolic reprogramming is a pragmatic strategy. CURGET is a five-node oral regimen designed to induce metabolic starvation in tumors.
    AREAS COVERED: Comprehensive literature search.The malignant phenotype features concurrent upregulation of glycolysis (HK2), glutaminolysis (GLS1), de novo lipogenesis (FASN), the mevalonate pathway (HMGR), and fatty-acid β-oxidation (FAO/3-KAT). CURGET combines four widely available polyphenols and a common cardiac drug: curcumin, urolithin A, resveratrol, EGCG, and trimetazidine to target these five enzymes. Additional mechanisms include context-dependent pro-oxidant activity and epigenetic modulation such as DNMT, HDAC, and HAT inhibition linked to cofactor depletion. This review synthesizes human safety and pharmacokinetic data, plasma AUC overlap with in vitro inhibitory concentrations, knockout evidence of metabolic plasticity, and clinical co-expression of HK2, GLS1, and FASN.
    EXPERT OPINION: CURGET represents a coherent, low-cost oral strategy rather than a finalized protocol. Key priorities include developing bioavailable formulations, conducting preclinical studies with defined metabolic endpoints, and early-phase pharmacokinetic and safety assessments of the combination. If CURGET shows a favorable therapeutic index, it may be most applicable to metabolically characterized tumors, including gastric, pancreatic, and selected breast cancers. Successful development could improve access to affordable metabolic adjuncts and help reduce global disparities in cancer care.
    Keywords:  CURGET; Cancer metabolism; drug repurposing; fatty-acid oxidation; fatty-acid synthesis; glutaminolysis; glycolysis; metabolic therapy; mevalonate pathway; polyphenols
    DOI:  https://doi.org/10.1080/14656566.2026.2749634
  16. Genes Dis. 2027 Feb;14(2): 102111
      Osteosarcoma, a highly invasive and metastatic malignant bone tumor, has a poor prognosis primarily because of early pulmonary metastasis and resistance to conventional treatments. The malignant progression of osteosarcoma cells significantly depends on glycometabolic reprogramming, a process characterized by enhanced aerobic glycolysis. This review begins by mapping the multi-dimensional networks driving sugar metabolism reprogramming, which revealed that functional abnormalities in core glycolytic enzymes, including hexokinase 2, pyruvate kinase M2, and lactate dehydrogenase A (LDHA), are driven by a multi-level regulatory network that includes altered transcription factor activity, epigenetic modifications, and interactions mediated by non-coding RNAs. Mitochondrial dysfunction leads to succinate and reactive oxygen species accumulation, synergistically promoting the remodeling of metabolic pathways. Furthermore, the synergistic interaction between the pentose phosphate pathway and glutamine metabolism accelerates the energy supply and biosynthesis, whereas lactate accumulation shapes the immunosuppressive microenvironment by inhibiting immune cell function. This review focuses on dissecting the core mechanisms of glucose metabolism reprogramming in osteosarcoma pathogenesis, including promoting proliferation, inhibiting apoptosis, enhancing invasion and metastasis, regulating immune metabolism, and mediating chemotherapy resistance. Additionally, it evaluates novel therapeutic strategies targeting key nodes of glucose metabolism in osteosarcoma, including advances in preclinical research on specific small-molecule inhibitors and gene regulatory approaches. Finally, it delves into the major challenges in translational research, such as metabolic heterogeneity, targeting selectivity, and compensatory resistance, as well as prospects for future research, including multi-omics analysis, smart delivery systems, organoid models, and combination immunotherapy. This study offers novel insights into overcoming the therapeutic bottlenecks in osteosarcoma treatment.
    Keywords:  Chemoresistance; Glycolysis; Lactylation; Metabolic reprogramming; Osteosarcoma; Therapeutic targeting
    DOI:  https://doi.org/10.1016/j.gendis.2026.102111
  17. Arch Biochem Biophys. 2026 Oct 12. pii: S0003-9861(26)00295-X. [Epub ahead of print]786 111022
      l-Asparaginase is a fundamental chemotherapeutic agent for acute lymphoblastic leukemia (ALL) that depletes circulating asparagine to induce apoptosis in leukemic blasts. However, the clinical administration of Escherichia colil-asparaginase is frequently limited by severe hepatotoxicity and neurotoxicity, which are directly driven by its off-target l-glutaminase co-activity. We hypothesized that rationally engineering the active-site flexible loop (ASFL), the dynamic motif that regulates substrate access, could decouple these catalytic activities. In this study, we present the structural and functional characterization of a novel E. colil-asparaginase variant harboring a targeted V27A mutation within the ASFL. Biophysical investigations using CD, FTIR, Raman spectroscopy, and dynamic light scattering reveal that this substitution triggers a profound conformational shift, characterized by increased α-helical content and significant structural compaction. This structural tightening not only enhances the enzyme's thermodynamic resistance to chemical denaturation but also improves substrate selectivity. Remarkably, p.V27A demonstrates a nearly two-fold increase in the Km for glutamine, significantly suppressing toxic off-target activity, while simultaneously lowering the Km for asparagine to improve therapeutic catalytic efficiency. Crucially, in vitro cytotoxicity assays against Jurkat T-ALL cells confirm that p.V27A retains potent anti-leukemic efficacy comparable to the wild-type enzyme. Together, our findings establish that targeted modification of the ASFL through the clinically relevant V27A substitution alters substrate discrimination, particularly by reducing productive accommodation of the larger l-glutamine substrate, while preserving l-asparagine catalytic function. By mechanically tuning these loop dynamics to favor specificity, we demonstrate that the p.V27A variant delivers an improved safety profile without compromising therapeutic potency, emerging as a highly promising candidate for next-generation leukemia therapy.
    Keywords:  Active-Site Flexible Loop (ASFL); Acute Lymphoblastic Leukemia (ALL); Glutaminase activity; Structure-function relationship; l-asparaginase
    DOI:  https://doi.org/10.1016/j.abb.2026.111022
  18. Food Res Int. 2026 Nov 30. pii: S0963-9969(26)02110-1. [Epub ahead of print]244 120423
      Metabolic dysfunction-associated steatotic liver disease (MASLD) is characterized by metabolic imbalances and lipid-induced cellular toxicity. Although postbiotics are emerging as reliable functional food ingredients for metabolic disorder management, molecular mechanisms underlying their hepatoprotective effects remain incompletely elucidated. In this study, we integrated microbial whole-genome sequencing with paired intracellular and extracellular metabolomic profiling to explore the regulatory effects of the Lacticaseibacillus paracasei CM6 postbiotic against sodium oleate/sodium palmitate (SO/SP)-induced lipotoxicity in HepG2 cells. Our results showed that CM6 postbiotic intervention significantly reduced intracellular triglyceride (TG) levels. Genomic analysis pinpointed key genes responsible for lipid regulation (bsh and ohyA) and involved in antioxidant defense and amino acid metabolism (gadC, gshA, proB/A) in the CM6 strain, suggesting its inherent potential to produce bioactive effectors. The CM6 postbiotic treatment significantly suppressed SREBF1-driven de novo lipogenesis (particularly ACACA) and enhanced fatty acid β-oxidation (marked by PPAR-α and CPT1A), in parallel with altered expression of key molecules in the FXR/AMPK signaling pathway. Furthermore, CM6 treatment significantly reduced the accumulation of lysophospholipids (LPCs, LysoPE), which was associated with downregulated PLA2G4A expression. Importantly, HepG2 cells treated with the CM6 postbiotic exhibited enhanced uptake of extracellular glutamate to support intracellular glutathione (GSH) biosynthesis, contributing to the clearance of reactive oxygen species (ROS) associated with lipotoxicity. Collectively, our findings suggest that the CM6 postbiotic alleviates SO/SP-induced hepatic lipotoxicity and steatosis-like phenotypes via concurrent modulation of lipid metabolism, cell membrane defense, and redox homeostasis, representing its potential as a novel bioactive dietary candidate and targeted nutritional strategy for MASLD management.
    Keywords:  HepG2 cells; Hepatic lipotoxicity; Lipid metabolism; Postbiotics; Redox homeostasis
    DOI:  https://doi.org/10.1016/j.foodres.2026.120423
  19. Cell Mol Immunol. 2026 Oct 16.
      Group 2 innate lymphoid cells (ILC2s) play a critical role in initiating the type 2 immune response, particularly in allergic airway diseases. Although the effects of glutamate on the immune system have been reported previously, its role in modulating the function of ILC2s and lung inflammation remains unclear.In this study, we report that the glutamate levels increased in lung tissue following exposure to allergens. Consequently, glutamate was found to restrain ILC2 responses during lung inflammation in mice. Using Rag1-/- mice, we demonstrated that the inhibitory effect of glutamate on type 2 inflammation was independent of T and B cells. Further ILC2 adoptive transfer experiments in Rag-/-Il2rg-/- mice confirmed that glutamate likely exerted its effects by directly targeting ILC2s. In vitro experiments revealed that glutamate suppressed ILC2 function through ionic kainate receptor signaling. Genetic deletion of the kainate receptor subunit GluK2 enhanced ILC2 responses and exacerbated type 2 lung inflammation. Mechanistically, transcriptome and metabolic analyses revealed that glutamate reduced oxidative metabolism in ILC2s, thereby limiting their activation. Consistently, in vivo administration of BPAM344-a positive allosteric modulator that potentiates GluK2 signaling-effectively suppressed allergen-induced type 2 inflammation. Notably, ILC2-specific GluK2 deletion markedly attenuated the anti-inflammatory effects of BPAM344, indicating that its protective effects depend on ILC2-intrinsic GluK2 signaling.These findings demonstrate a novel role for glutamate in restraining ILC2 function, as it plays a protective role in alleviating airway inflammation. We propose that GluK2 activation may offer a promising therapeutic strategy for treating ILC2-driven allergic asthma.
    Keywords:  GluK2; Glutamate; ILC2; Type 2 lung inflammation
    DOI:  https://doi.org/10.1038/s41423-026-01461-4
  20. Free Radic Biol Med. 2026 Oct 13. pii: S0891-5849(26)01222-0. [Epub ahead of print]
      Glutamate can disrupt cystine-dependent glutathione metabolism and promote oxidative and mitochondrial dysfunction in neural cells. We integrated human multiple-sclerosis optic-chiasm transcriptomics (GSE100297), glutamate-treated primary-neuron RNA sequencing (GSE255041), R28 differential-expression summaries, a normal human optic-nerve single-nucleus atlas (GSE236566), and R28 retinal precursor-cell experiments to characterize glucosamine (GlcN) and selenium responses. Human tissue showed enriched unfolded-protein-response, oxidative-stress, apoptosis, and ferroptosis programs, whereas glutamate-treated neurons predominantly exhibited amino-acid stress, unfolded-protein response, oxidative stress, and apoptosis, with weaker concordant ferroptosis enrichment. Glutamate reduced R28 metabolic activity, GSH/GSSG, and mitochondrial respiration and increased DCFH-DA and BODIPY-C11 oxidation. GlcN (2.5 mM) shifted the glutamate dose-response curve rightward and preserved GSH/GSSG and respiration, but lowered basal metabolic activity, mitochondrial membrane potential, and ATP-based viability. GlcN increased the LC3B-II/LC3B-I ratio, while changes in PCNA-normalized NRF2-related protein signals were modest. Ferrostatin-1 (Fer-1) partially restored respiration during glutamate exposure and was associated with higher ATP-based viability. RSL3 and erastin markedly reduced viability without glutamate; Fer-1 substantially restored viability, whereas GlcN did not. Selenium (1 μM) partially reduced RSL3-associated loss of viability without glutamate; the selenium-associated viability gain diminished during glutamate co-exposure (adjusted interaction P=0.0342). Selenium showed dose-dependent effects: 1 and 5 μM preserved metabolic activity, 5 μM reduced lipid oxidation, and 20 μM increased basal lipid oxidation. GlcN increased global O-GlcNAc modification approximately 3.6-fold and altered gp130 migration. In normal human optic nerve, redox/lipid-peroxidation programs were highest in myeloid cells, whereas hexosamine/O-GlcNAc capacity and SLC7A11 expression were prominent in astrocytic-stromal compartments. These findings identify distinct functional responses to GlcN and selenium within a mixed glutamate-stress phenotype that includes a ferrostatin-sensitive component. The GPX4 dependence of GlcN-mediated protection against glutamate remains unresolved.
    Keywords:  GPX4; O-GlcNAc; ferroptosis-related signaling; glucosamine; glutamate; glutathione; lipid peroxidation; mitochondrial respiration; redox signaling; selenium
    DOI:  https://doi.org/10.1016/j.freeradbiomed.2026.10.031
  21. FEBS J. 2026 Oct 14.
      Enteroendocrine L cells function as chemosensors in the intestine, secreting glucagon-like peptide-1 (GLP-1) to signal nutrient ingestion to the brain. Since GLP-1 secretion is induced by a variety of nutrients, including sugars, amino acids, and fatty acids, GLP-1 receptor-expressing neurons are also activated regardless of the nutrient identity, making it unclear how the brain discriminates between different nutrients. By examining vesicle dynamics and extracellular signals associated with GLP-1, glutamate, and ATP in GLUTag cells using total internal reflection fluorescence (TIRF) microscopy, a technique that selectively visualizes fluorescent molecules near the plasma membrane, we demonstrated that distinct nutrients evoke specific secretory patterns. D-glucose induced the co-secretion of GLP-1, glutamate, and ATP, whereas L-glutamine induced the secretion of GLP-1 and glutamate but not ATP. Butyrate and sucralose, which are also GLP-1 secretagogues, did not induce the secretion of glutamate or ATP. While Ca2+ acts as the trigger for exocytosis, additional regulatory mechanisms are required to generate these distinct secretory patterns. We therefore investigated the cAMP and cGMP pathways and found that neither their activation nor inhibition detectably affected glutamate and ATP secretion, suggesting the involvement of other nutrient-specific signaling pathways. Collectively, our findings suggest that L cells distinguish and encode nutrient identity as combinatorial secretion patterns of GLP-1 and neurotransmitters.
    Keywords:  ATP; cell signaling; exocytosis; glucagon‐like peptide‐1; glutamate
    DOI:  https://doi.org/10.1111/febs.70753